This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Iovance Biotherapeutics Securities...
Business securities lawsuit

Iovance Biotherapeutics Securities Fraud Lawsuit

Analysis based on 25 articles · First reported May 19, 2025 · Last updated Jun 28, 2025

Sentiment
-70
Attention
4
Articles
25
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The lawsuit against Atara Biotherapeutics for alleged securities fraud has caused its stock price to decline by over 44%, indicating significant negative market sentiment for the company. This event highlights the risks associated with product launch dynamics and investor communication in the biotechnology sector.

biotechnology pharmaceuticals legal services
Event Summary

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Atara Biotherapeutics and its senior executives. The lawsuit alleges that Atara Biotherapeutics misled investors regarding the demand for its melanoma treatment, Amtagvi, and the effectiveness of its authorized treatment centers (ATCs). The company had reportedly touted its ATCs as a key driver of demand, but in reality, they experienced long treatment timelines and high patient drop-offs due to ineffective patient identification and selection. This alleged misrepresentation came to light on May 8, 2025, when Atara Biotherapeutics reported disappointing financial results for 1Q25 and revised its full-year 2025 revenue guidance, attributing the poor performance to 'recent launch dynamics' and issues with ATCs. Following this news, the stock price of Atara Biotherapeutics plummeted by more than 44%. Investors have until July 14, 2025, to seek appointment as lead plaintiff in the case, which is pending in the U.S. District Court for the Northern District of California.

Key Actions
100 Bleichmar Fonti & Auld LLP filed lawsuit Atara Biotherapeutics
92 Atara Biotherapeutics reported financial results
Entities Involved
stock
Atara Biotherapeutics
Atara Biotherapeutics is facing a securities fraud class action lawsuit for allegedly misleading investors about the demand for its melanoma treatment, Amtagvi, and its authorized treatment centers. This led to a significant drop in its stock price.
Importance 100.0 Sentiment -80.0
per
Ross Shikowitz
Importance 0.0 Sentiment 0.0
priv
Bleichmar Fonti & Auld LLP
Importance 0.0 Sentiment 0.0
stock
Tesla, Inc.
Importance 0.0 Sentiment 0.0
stock
Sun Pharma
Importance 0.0 Sentiment 0.0
Relationships
Ross Shikowitz partner ↔ Bleichmar Fonti & Auld LLP Ross Shikowitz is a partner at the law firm Bleichmar Fonti & Auld LLP, where he focuses on securities and corporate gov
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.